The inclusion of eight new INNs in the subsidized drug provision program list for patients who have suffered acute cardiovascular events will reduce mortality and hospitalization of patients with heart failure, said Elena Astapenko, Director of the Department of Drug Supply and Regulation of the Circulation of Medical Devices of the Ministry of Health at the Cardiovascular Diseases and Life Expectancy forum on September 15. She noted that the new drugs will contribute to the coverage of 172,000 more heart failure patients. This is reported by MV.
According to Nadezhda Zvartau, Deputy Director for work with regions of the Almazov National Medical Reseach Center, experts believe that the drug provision for this category of patients will help to save 30,000 lives in three years.
Earlier, the Ministry of Health presented changes to the list of drugs for patients not included into subsidized categories who have suffered acute cerebral circulatory disorders, myocardial infarction, as well as for those who have undergone coronary artery bypass graft surgery, coronary artery angioplasty with stenting and catheter ablation for cardiovascular diseases treatment, the publication reported. It is proposed to add acetazolamide, sacubitril/valsartan, ivabradine, dapagliflozin, digoxin, spironolactone, furosemide, and empagliflozin to the list, which already includes 23 INNs. Astapenko drew attention to the fact that as of September 1, the number of patients provided with drugs under this program had been 652,000, compared to 673,000 over 2021 and 450,000 in 2020.
Oksana Drapkina, Director of the NMRC of Therapy and Preventive Medicine, added that the issue of expanding the program to patients with coronary heart disease and arterial hypertension with concomitant diseases is being considered.